{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:02:27Z","timestamp":1775674947452,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02901-1","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:02:42Z","timestamp":1718434962000},"page":"3396-3406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diroximel Fumarate in Patients with Relapsing\u2013Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase\u00a03 EVOLVE-MS-1 Study"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03093324","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-250X","authenticated-orcid":false,"given":"James D.","family":"Bowen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Stulc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0542-1176","authenticated-orcid":false,"given":"Samuel F.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Scaramozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2205-4233","authenticated-orcid":false,"given":"Ivan","family":"Bozin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Then Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"2901_CR1","unstructured":"European Medicines Agency: Vumerity summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vumerity-epar-product-information_en.pdf. 2022. Accessed 11 Jul 2023."},{"key":"2901_CR2","unstructured":"VUMERITY\u00ae (diroximel fumarate) Prescribing Information. Biogen, Cambridge, MA. 2023."},{"issue":"13","key":"2901_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase\u00a03 EVOLVE-MS-1 study. Mult Scler. 2020;26(13):1729\u201339. https:\/\/doi.org\/10.1177\/1352458519881761.","journal-title":"Mult Scler"},{"issue":"14","key":"2901_CR4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1177\/13524585231205708","volume":"29","author":"BA Singer","year":"2023","unstructured":"Singer BA, Arnold DL, Drulovic J, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase\u00a03 EVOLVE-MS-1 study. Mult Scler. 2023;29(14):1795\u2013807. https:\/\/doi.org\/10.1177\/13524585231205708.","journal-title":"Mult Scler"},{"key":"2901_CR5","unstructured":"Biogen. Data on file. 2024."},{"key":"2901_CR6","unstructured":"TECFIDERA\u00ae (dimethyl fumarate) Prescribing Information. Biogen, Cambridge, MA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204063s029lbl.pdf Accessed May\u00a025, 2023."},{"key":"2901_CR7","doi-asserted-by":"crossref","unstructured":"Wehr A, Hard M, Yu M, Leigh-Pemberton R, von Moltke L. Relative bioavailability of monomethyl fumarate after administration of ALKS 8700 and dimethyl fumarate in healthy subjects (P1.403). Neurology. 2018;90(15 Supplement):P1.403.","DOI":"10.1212\/WNL.90.15_supplement.P1.403"},{"issue":"2","key":"2901_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase\u00a0III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185\u201396. https:\/\/doi.org\/10.1007\/s40263-020-00700-0.","journal-title":"CNS Drugs"},{"key":"2901_CR9","doi-asserted-by":"publisher","first-page":"175628642199399","DOI":"10.1177\/1756286421993999","volume":"14","author":"A Wundes","year":"2021","unstructured":"Wundes A, Wray S, Gold R, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase\u00a0III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021;14:1756286421993999. https:\/\/doi.org\/10.1177\/1756286421993999.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2901_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/ene.15171","volume":"29","author":"P Vermersch","year":"2022","unstructured":"Vermersch P, Oreja-Guevara C, Siva A, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: a primary analysis from the phase\u00a03b CASTING single-arm, open-label trial. Eur J Neurol. 2022;29(3):790\u2013801. https:\/\/doi.org\/10.1111\/ene.15171.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2901_CR11","doi-asserted-by":"publisher","first-page":"205521731876064","DOI":"10.1177\/2055217318760642","volume":"4","author":"E Havrdova","year":"2018","unstructured":"Havrdova E, Arnold DL, Bar-Or A, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4(1):2055217318760642. https:\/\/doi.org\/10.1177\/2055217318760642.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"2901_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/ene.15121","volume":"29","author":"CV Russo","year":"2022","unstructured":"Russo CV, Sacca F, Frau J, et al. A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol. 2022;29(1):257\u201366. https:\/\/doi.org\/10.1111\/ene.15121.","journal-title":"Eur J Neurol"},{"key":"2901_CR13","doi-asserted-by":"publisher","first-page":"1034056","DOI":"10.3389\/fneur.2022.1034056","volume":"13","author":"CS Simonsen","year":"2022","unstructured":"Simonsen CS, Flemmen HO, Broch L, Brekke K, Brunborg C, Berg-Hansen P, et al. Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population. Front Neurol. 2022;13:1034056. https:\/\/doi.org\/10.3389\/fneur.2022.1034056.","journal-title":"Front Neurol"},{"issue":"15 Suppl","key":"2901_CR14","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1212\/WNL.96.15_supplement.2190","volume":"96","author":"BA Singer","year":"2021","unstructured":"Singer BA, Shafer SJ, Arnold DL, et al. Diroximel fumarate and dimethyl fumarate demonstrate early radiological efficacy in relapsing-remitting multiple sclerosis (2190). Neurology. 2021;96(15 Suppl):2190.","journal-title":"Neurology"},{"issue":"12","key":"2901_CR15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2019-321321","volume":"90","author":"T Sejbaek","year":"2019","unstructured":"Sejbaek T, Nielsen HH, Penner N, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry. 2019;90(12):1324\u201330. https:\/\/doi.org\/10.1136\/jnnp-2019-321321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2901_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","volume":"12","author":"SD Newsome","year":"2023","unstructured":"Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [narrative review]. Neurol Ther. 2023;12(6):1909\u201335. https:\/\/doi.org\/10.1007\/s40120-023-00549-7.","journal-title":"Neurol Ther"},{"issue":"2","key":"2901_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2901_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254\u201360. https:\/\/doi.org\/10.1016\/S1474-4422(09)70021-3.","journal-title":"Lancet Neurol"},{"key":"2901_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12883-014-0240-x","volume":"14","author":"DL Arnold","year":"2014","unstructured":"Arnold DL, Calabresi PA, Kieseier BC, et al. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol. 2014;14:240. https:\/\/doi.org\/10.1186\/s12883-014-0240-x.","journal-title":"BMC Neurol"},{"issue":"5","key":"2901_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase\u00a03 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78(5):558\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2901_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12883-022-02761-8","volume":"22","author":"N Sattarnezhad","year":"2022","unstructured":"Sattarnezhad N, Healy BC, Baharnoori M, et al. Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. BMC Neurol. 2022;22(1):252. https:\/\/doi.org\/10.1186\/s12883-022-02761-8.","journal-title":"BMC Neurol"},{"key":"2901_CR22","doi-asserted-by":"publisher","first-page":"175628641879640","DOI":"10.1177\/1756286418796404","volume":"11","author":"E D'Amico","year":"2018","unstructured":"D\u2019Amico E, Zanghi A, Callari G, et al. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience. Ther Adv Neurol Disord. 2018;11:1756286418796404. https:\/\/doi.org\/10.1177\/1756286418796404.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"2901_CR23","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1212\/WNL.0000000000005772","volume":"91","author":"L Prosperini","year":"2018","unstructured":"Prosperini L, Lucchini M, Haggiag S, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: a real-world propensity score-matched study. Neurology. 2018;91(2):e153\u201361. https:\/\/doi.org\/10.1212\/WNL.0000000000005772.","journal-title":"Neurology"},{"issue":"4","key":"2901_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329\u201333. https:\/\/doi.org\/10.1016\/j.msard.2015.04.006.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"2901_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","volume":"17","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17(5):236\u201343. https:\/\/doi.org\/10.7224\/1537-2073.2014-069.","journal-title":"Int J MS Care"},{"issue":"3","key":"2901_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6(3):220\u20139. https:\/\/doi.org\/10.1212\/CPJ.0000000000000238.","journal-title":"Neurol Clin Pract"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02901-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:11:33Z","timestamp":1721675493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02901-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2901"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02901-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"James D. Bowen: speaker\/consulting\/advisory fees from Alexion, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, and TG Therapeutics; holds stock in Amgen; research support from Alexion, Alkermes, Biogen, Celgene, Genzyme, Genentech, Novartis, and TG Therapeutics. Jessica Stulc: advisory\/data safety monitoring boards for EMD Serono; speaker bureaus for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, and Sanofi; research support from Biogen, EMD Serono, Genentech, Novartis, Sanofi, and TG Therapeutics. Samuel F. Hunter: received consulting fees from Alexion, Biogen, BMS, Genentech, Horizon, Janssen, Sanofi, and Serono; contracted research for Anokion, Atara, Biogen, Genentech, Janssen, and Sanofi; and served on speaker bureaus for Biogen, BMS, EMD Serono, Horizon, and Janssen. Hailu Chen: employee of and held stock\/stock options in Biogen at the time of this work; current employee of and holds stock\/stock options in Alkermes. James B. Lewin, Matthew Scaramozza, and Ivan Bozin: employees of Biogen and may hold stock in the company. Florian Then Bergh: research support and travel grants, through his institution, from the German Science Fund (DFG), German Federal Ministry of Education and Science (BMBF), Bayer-Schering, Merck, Novartis, Pfizer, Roche, Sanofi, and Teva and speaker fees from and advisory boards for Actelion, Alexion, Bayer, Biogen, CSL Behring, Fresenius, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"EVOLVE-MS-1 was approved by local and central ethics committees and conducted in accordance with International Council on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki []. All patients provided written, informed consent. Ethical approval was not applicable for this analysis as data were based on existing outputs from the EVOLVE-MS-1 study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}